Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

811 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the therapeutic equivalence of the lest formulation of Mometasone Furoate Nasal Spray, 50 mcg to the marketed formulation NASONEX® (mometasone furoate monohydrate) Nasal Spray, 50 mcg/actuation in patients with seasonal allergic rhinitis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01038427

Rhinitis, Allergic, Seasonal

COMPLETED PHASE3

Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation

NCT01523236

Seasonal Allergic Rhinitis

COMPLETED PHASE1/PHASE2

A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers

NCT02109185

Treatment of the Signs and Symptoms of Seasonal Allergic Rhinitis

COMPLETED PHASE1

A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)

NCT01673659

Seasonal Allergic Rhinitis

COMPLETED PHASE3

Clinical Equivalence Study of Mometasone Nasal Spray

NCT01850823

Seasonal Allergic Rhinitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seasonal Allergic Rhinitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mometasone Furoate Nasal Spray, 50 mcg

Mometasone Furoate Nasal Spray, 50 mcg. 4 actuations per day for 14 days.

Group Type EXPERIMENTAL

Mometasone Furoate Nasal Spray, 50 mcg

Intervention Type DRUG

a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate

Nasonex Nasal Spray, 50 mcg

Nasonex (mometasone furoate monohydrate) Nasal Spray, 50 mcg. 4 actuations per day for 14 days.

Group Type ACTIVE_COMPARATOR

Nasonex Nasal Spray, 50 mcg

Intervention Type DRUG

a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate

Placebo Nasal Spray

Placebo of Mometasone Furoate Nasal Spray. 4 actuations per day for 14 days.

Group Type PLACEBO_COMPARATOR

Placebo Nasal Spray

Intervention Type DRUG

a metered-dose, manual pump spray unit containing an aqueous suspension

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mometasone Furoate Nasal Spray, 50 mcg

a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate

Intervention Type DRUG

Nasonex Nasal Spray, 50 mcg

a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate

Intervention Type DRUG

Placebo Nasal Spray

a metered-dose, manual pump spray unit containing an aqueous suspension

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* If female and of child-bearing potential, have a negative urine pregnancy test and is prepared to abstain from sexual intercourse or use a reliable method of contraception during the study
* Documented positive allergic skin test, performed within the previous 12 months, to one or more of the allergens in season at the time the study is being conducted.
* A minimum of two consecutive years of previous history of seasonal allergic rhinitis to the pollen/allergen in season at the time the study is being conducted.
* A score of at least 6 on the reflective Total Nasal Symptom Score (rTNSS) and a minimum score of at least 2 for "nasal congestion" and a minimum score of at least 2 for one of the remaining 3 symptoms representing the 12hours prior to the screening visit.
* An average composite score of at least 6 on the rTNSS and a minimum score of at least 2 for "nasal congestion" and a minimum score of at least 2 for one of the remaining 3 symptoms representing the last 3 days of the 7-day placebo lead-in period before the randomization visit and the morning of the first day.

of the randomization visit.

Exclusion Criteria

* Females who are pregnant, lactating or likely to become pregnant during the study.
* Negative or lack of documented skin allergen test (performed within the previous 12 months) to at least one of the allergens in season at the time the study is being conducted.
* Patients who suffer from chronic signs and symptoms of Perennial Allergic Rhinitis, unless the investigator assesses that the patient's current signs and symptoms are a clear exacerbation of Seasonal Allergic Rhinitis (SAR) rather than chronic PAR.
* Patients who suffer only from perennial allergic rhinitis or seasonal allergic rhinitis to a different allergen than that in season at the time the study is conducted.
* Previous history of less than 2 years of seasonal allergic rhinitis to the pollen/allergen in season at the time the study is being conducted.
* Any patient who meets the minimum rTNSS requirements at the start of the placebo lead-in period but no longer meets the requirements prior to the randomized active treatment period of the study cannot continue in the active treatment period.
* History of asthma over the previous two years that required chronic therapy. Occasional acute or mild exercise induced asthma will be allowable on the condition that the treatment of the attacks is restricted to beta-agonists only.
* Patients with nasal conditions, including infectious rhinitis, rhinitis medicamentosa or atrophic rhinitis.
* Clinically significant nasal deformity or any recent nasal surgery or trauma that has not completely healed.
* Sinus infection within the previous 30 days or history of reoccurring sinus infections.
* Patient has started immunotherapy or changed their dose of immunotherapy within 30 days of the first placebo lead-in dose or is likely to have to start immunotherapy, or change their current dose during the study.
* Treatment for oral Candidiasis within 30 days of starting the study or a current oral Candidiasis infection.
* Upper respiratory tract infection within the previous 30 days.
* Patients with a history of tuberculosis.
* Patients with the presence of glaucoma, cataracts, ocular herpes simplex, conjunctivitis or other eye infection not related to the diagnosis of SAR within 14 days of enrollment.
* The patient has had recent exposure (30 days) or was at risk of being exposed to chicken pox or measles.
* Patients with any untreated fungal, bacterial, systemic viral infections within the previous 30 days.
* Use of any ophthalmic steroids within 14 days or nasal, inhaled or systemic steroids within 30 days of the study start.
* Use of the reference product, Nasonex® within 3 months of the study start.
* Use of intranasal or systemic second-generation anti-histamines within10 days of enrollment.
* Use of intranasal cromolyn within 14 days of enrollment.
* Use of intranasal or systemic first-generation anti-histamines, leukotriene receptor antagonists or other nasal decongestants within 3 days of enrollment.
* Use of any tricyclic anti-depressant within 30 days of enrollment
* Patients with attention-deficit disorder being treated with methylphenidate containing products that have not been on a stable dosing regimen for at least the 30 previous days and who cannot remain on the same dosing regimen throughout the study.
* Desensitization therapy to the seasonal allergen that is causing the patients allergic rhinitis within the previous 6 months.
* Previous SAR and/or PAR that has proven unresponsive to steroid therapy.
* Any known hypersensitivity to mometasone, other steroids or any of the components of the study nasal spray.
* Significant history or current evidence of chronic infectious disease, system disorder, organ disorder or other medical condition that in the Investigator's opinion would place the study patient at undue risk by participating or could jeopardize the integrity of the study evaluations.
* Receipt of any drug as part of a research study within 30 days prior to the first placebo lead-in dose.
* Planned travel outside of the local area for more than 2 consecutive days or 3 days in total, during the patient's participation in the study.
* Previous participation in this study.
* The patient currently smokes cigarettes, cigars, and/or pipes and is a heavy smoker
* The patient shares a household with another patient currently enrolled in this study

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No